花园生物(300401) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥326,391,133.03, a decrease of 1.18% compared to ¥330,273,302.02 in the same period last year[6] - Net profit attributable to shareholders increased by 5.50% to ¥96,511,379.04 from ¥91,483,091.72 year-on-year[6] - The net profit after deducting non-recurring gains and losses surged by 44.42% to ¥88,138,393.32 compared to ¥61,030,303.01 in the previous year[6] - Total operating revenue for the current period was ¥326,391,133.03, a decrease of 1.7% from ¥330,273,302.02 in the previous period[22] - Net profit for the current period was ¥96,509,841.11, up 5.6% from ¥91,483,091.72 in the previous period[23] - Earnings per share increased to ¥0.18 from ¥0.17, indicating a growth of 5.9%[23] Cash Flow and Investments - The net cash flow from operating activities rose by 29.70% to ¥144,056,264.68 from ¥111,071,221.09 year-on-year[6] - Operating cash inflow for the current period was $390,437,025.51, slightly up from $388,596,451.91 in the previous period, indicating a growth of approximately 0.22%[25] - Cash outflow from investing activities decreased to $196,939,714.12 from $705,581,140.41, showing a reduction of approximately 72%[25] - Net cash flow from investing activities improved to -$196,939,714.12 from -$325,625,112.24, reflecting a 39.5% reduction in cash outflow[25] - The company’s cash flow from operating activities remains strong, with a net increase despite challenges in financing activities[25][26] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,536,546,355.58, a decrease of 1.36% from ¥5,612,645,527.96 at the end of the previous year[6] - Total liabilities decreased to ¥2,193,883,495.20 from ¥2,394,249,260.65, representing a reduction of approximately 8.4%[21] - Total equity attributable to shareholders increased to ¥3,342,668,208.44 from ¥3,218,400,077.44, reflecting a growth of about 3.9%[21] - The company's cash and cash equivalents decreased from CNY 1,284,473,292.97 to CNY 1,055,421,957.77, a decline of approximately 17.8%[19] - The company reported a total current asset of CNY 2,263,623,163.71, down from CNY 2,469,407,256.94, indicating a decrease of approximately 8.3%[19] Shareholder Information - Shareholders' equity attributable to the parent company increased by 3.86% to ¥3,342,668,208.44 from ¥3,218,400,077.44 at the end of the previous year[6] - The number of ordinary shareholders at the end of the reporting period was 27,868[15] Operational Efficiency - Total operating costs decreased to ¥225,274,384.48 from ¥260,819,419.20, reflecting a reduction of approximately 13.6%[22] - The company reported a significant reduction in financial expenses, which fell to ¥3,671,625.11 from ¥7,527,764.01, a decrease of about 51.2%[22] - Research and development expenses were ¥16,376,140.28, down from ¥20,557,191.99, a decrease of approximately 20.5%[22] Future Outlook - Future performance guidance remains optimistic, with expectations for improved financial metrics in the upcoming quarters[18] - The company is focusing on new product development and market expansion strategies, although specific details were not provided in the call[18] - The company has not disclosed any significant mergers or acquisitions during this reporting period[18]